Skye Bioscience Inc (SKYE): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Skye Bioscience Inc (SKYE) following the 2026 Q1 hedge fund 13F filings?

As of today, SKYE has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), SKYE gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Skye Bioscience Inc (SKYE)

38 + Investors. Track Smart Money conviction in SKYE. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — SKYE

Based on 38 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 4 quarters in a row

last 6Q

For 4 consecutive quarters, more hedge funds reduced or closed their SKYE positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

🔻

Below peak — only 52% of 3.0Y high

52% of all-time peak

Only 38 funds hold SKYE today versus a peak of 73 funds at 2025 Q1 — just 52% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.

📉

Outflows — 48% fewer funds vs a year ago

fund count last 6Q

35 fewer hedge funds hold SKYE compared to a year ago (-48% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.

🔴

Heavy selling pressure — only 35% buying

13 buying24 selling

Last quarter: 24 funds sold vs only 13 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

⚠️

Fewer new buyers each quarter (-10 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 15 → 14 → 14 → 4. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔄

Mostly new holders — 34% entered in last year

■ 8% conviction (2yr+) ■ 58% medium ■ 34% new

Only 3 funds (8%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💎

Buying through price weakness — shares +0%, value -18%

Value

-17%

+0%

Last quarter: funds added +0% more shares while total portfolio value only changed -18%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📊

Peak discovery — momentum slowing

13 → 15 → 14 → 14 → 4 new funds/Q

New funds entering each quarter: 15 → 14 → 14 → 4. SKYE is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.

📊

Mixed cohorts — 3% veterans, 28% new entrants

■ 3% veterans ■ 69% 1-2yr ■ 28% new

Of 39 current holders: 1 (3%) held 2+ years, 27 held 1–2 years, 11 (28%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

📋

Smaller funds dominant — 4% AUM from top-100

4% from top-100 AUM funds

9 of 37 holders rank in the top 100 by AUM, but together hold only 4% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

2.2

out of 10

Low Exit Risk

Exit risk score 2.2/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	38	49	-22.45%
13F Shares	16M	16M	0.31%
Total Value	$10M	$12M	-17.71%
New Positions	4	14	-10
Increased Positions	9	6	+3
Closed Positions	15	22	-7
Reduced Positions	8	10	-2
Total Calls	1	1	-
Total Puts	1	1	-
PUT/CALL Ratio	1.0	1.0	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

-22.45%

13F Shares

16M

0.31%

Total Value

$10M

$12M

-17.71%

New Positions

-10

Increased Positions

Closed Positions

-7

Reduced Positions

-2

Total Calls

Total Puts

PUT/CALL Ratio

1.0

Neutral

Institutional Holders (2026 Q1)

38 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in SKYE. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 SKYE holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	5AM Venture Management, LLC	1.65%	9,681,763	$6.0M
2	Versant Venture Management, LLC	0.87%	2,007,704	$1.2M
3	Sphera Funds Management LTD.	0.07%	678,928	$417K
4	Platinum Investment Management Ltd	0.04%	233,095	$143K
5	Baker BROS. Advisors LP	0.01%	1,575,243	$968K
6	XTX Topco Ltd	0.00%	40,919	$25K
7	Engineers Gate Manager LP	0.00%	20,194	$12K
8	Millennium Management LLC	0.00%	258,200	$159K
9	Two Sigma Advisers, LP	0.00%	40,982	$31K
10	Vanguard Fiduciary Trust Co	0.00%	104,229	$64K
11	Two Sigma Investments, LP	0.00%	25,684	$16K
12	Vanguard Capital Management LLC	0.00%	764,457	$470K
13	Group One Trading LLC	0.00%	7,205	$4K
14	Citadel Advisors LLC	0.00%	59,800	$37K
15	UBS Group AG	0.00%	45,762	$28K
16	Citadel Advisors LLC	0.00%	39,100	$24K
17	BlackRock, Inc.	0.00%	286,131	$176K
18	Barclays plc	0.00%	18,089	$11K
19	Federated Hermes, INC.	0.00%	1,158	—
20	Leo H. Evart, Inc.	0.00%	1	—
21	Mcguire Capital Advisors Inc	0.00%	2	—
22	Osaic Holdings, INC.	0.00%	600	—
23	PFS Partners, LLC	0.00%	1	—
24	National Bank of Canada /Fi/	0.00%	400	—
25	CoreCap Advisors, LLC	0.00%	8	—

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Skye Bioscience Inc (SKYE)

What does the Smart Money Trend signal show for SKYE?

Selling streak — 4 quarters in a row: For 4 consecutive quarters, more hedge funds reduced or closed their SKYE positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for SKYE?

Heavy selling pressure — only 35% buying: Last quarter: 24 funds sold vs only 13 buyers. This is widespread institutional distribution — not a few funds rebalancing, but a broad exit. High conviction bearish signal.

What is the fund quality score for SKYE holders?

Smaller funds dominant — 4% AUM from top-100: 9 of 37 holders rank in the top 100 by AUM, but together hold only 4% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held SKYE?

Mostly new holders — 34% entered in last year: Only 3 funds (8%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Skye Bioscience Inc (SKYE) following the 2026 Q1 hedge fund 13F filings?

As of today, SKYE has moved nan% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.2% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), SKYE has gained nan% vs +2.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Skye Bioscience Inc (SKYE)

Smart Money Signals — SKYE

Selling streak — 4 quarters in a row

Below peak — only 52% of 3.0Y high

Outflows — 48% fewer funds vs a year ago

Heavy selling pressure — only 35% buying

Fewer new buyers each quarter (-10 vs last Q)

Mostly new holders — 34% entered in last year

Buying through price weakness — shares +0%, value -18%

Peak discovery — momentum slowing

Mixed cohorts — 3% veterans, 28% new entrants

Smaller funds dominant — 4% AUM from top-100

Institutional Sentiment Summary — SKYE

Hedge Fund Ownership: SKYE

Market Analysis: SKYE

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: SKYE

Is It Too Late to Buy Skye Bioscience Inc (SKYE) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: SKYE

Statistics: SKYE

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Skye Bioscience Inc (SKYE)

Welcome to 13Foresight!